GIP and obesity due to melanocortin 4 receptor deficiency: This drug, based on the GIP sequence and attached to a C20 diacid moiety, was developed by Eli Lilly and approved by the FDA and EMA in 2022 for the treatment of adults with obesity or overweight with weight-related comorbidities [64].